ABSTRACT. Phototherapy results in the conversion of native bilirubin to more water-soluble configurational and structural isomers. The serum half-life for the configurational isomer, the principal photoproduct in vivo, was determined by high pressure liquid chromatography in six premature infants following cessation of phototherapy. The mean half-life for this isomer was 15 h. The excretion of this isomer, calculated from the measured half-life, is less than half of daily bilirubin production, and therefore cannot account for the total bilirubin elimination observed during phototherapy. The serum concentration of the structural isomer, lumirubin, is lower than that of the configurational isomer; however, excretion is more rapid (serum half-life < 2 h). Because of its rapid excretion, lumirubin may be an important pathway for bilirubin elimination during phototherapy. (Pediatr Res 19: 205-208, 1985) Abbreviation HPLC, high pressure liquid chromatography Despite the widespread use of phototherapy in the treatment of neonatal hyperbilirubinemia (l), the detailed mechanism by which visible light affects bilirubin metabolism in jaundiced newborns is not known. The purpose of this study was to measure the rate of elimination of the principal bilirubin photoproduct, 4Z,15E-bilirubin, and to determine whether this is sufficient to Received June 22, 1984; accepted October 3, 1984. Address account for the decline in plasma bilirubin observed during phototherapy.
ABSTRACT. Phototherapy results in the conversion of native bilirubin to more water-soluble configurational and structural isomers. The serum half-life for the configurational isomer, the principal photoproduct in vivo, was determined by high pressure liquid chromatography in six premature infants following cessation of phototherapy. The mean half-life for this isomer was 15 h. The excretion of this isomer, calculated from the measured half-life, is less than half of daily bilirubin production, and therefore cannot account for the total bilirubin elimination observed during phototherapy. The serum concentration of the structural isomer, lumirubin, is lower than that of the configurational isomer; however, excretion is more rapid (serum half-life < 2 h). Because of its rapid excretion, lumirubin may be an important pathway for bilirubin elimination during phototherapy. (Pediatr Res 19: 205-208, 1985) Abbreviation HPLC, high pressure liquid chromatography Despite the widespread use of phototherapy in the treatment of neonatal hyperbilirubinemia (l), the detailed mechanism by which visible light affects bilirubin metabolism in jaundiced newborns is not known. The purpose of this study was to measure the rate of elimination of the principal bilirubin photoproduct, 4Z,15E-bilirubin, and to determine whether this is sufficient to account for the decline in plasma bilirubin observed during phototherapy.
Bilirubin, derived from the degradation of heme, is a potentially toxic, highly lipophylic molecule. In mammals this pigment is ravidlv cleared from the circulation and excreted as a ducuronide~onju~ate, primarily in the bile (2). Newborn i n f a k commonly develop hyperbilirubinemia due in part to a decreased ability to conjugate bilirubin and an increased pigment load. During vhototheravy, the most commonlv used treatment for unconj~~ated&~~dilirubinemia, bilirubin undergoes several reactions (3-7). All of these reactions yield photoproducts which are more polar and therefore presumably more easily excreted than native bilirubin. The fastest photochemical reaction is a Z to E isomerization reaction (5, 8) which in human infants yields primarily the 4Z,15E-bilirubin isomer (6) . This reaction is readily reversible and up to 20% of the total bilirubin can be converted to this isomer during phototherapy (9) (10) (11) (12) .
Since the quantum yield of the configurational isomerization reaction is at least 40 times greater than that for any other photochemical reaction of bilirubin (8), it has been assumed that the elimination of bilirubin during phototherapy is the result of formation and excretion of this photoproduct. We have used a rapid, quantitative HPLC method (5) to measure the half-life of the configurational isomer in serum of preterm infants undergoing phototherapy. We have found that the rate of elimination of the 4Z,15E-bilirubin isomer is much slower than previously reported (13) and cannot account for the decline in serum bilirubin observed in infants treated with phototherapy.
METHODS
Patients. The study population included six premature infants in our level I1 nursery with a mean gestational age of 30 wk and a mean birth weight of 1.3 kg. All infants were treated with phototherapy from a bank of eight daylight fluorescent lamps housed in a standard canopy. The irradiance in the 400 to 500 nm spectral region (measured as described below) was approximately 5 x W/cm2 at a distance of 50 cm from this phototherapy unit. This compares with an ambient light irradiance in the same spectral region between 0.3 and 3 x lo-' W/ cm2 in the level I1 nursery. Decisions on the initiation and termination of phototherapy were based on standard clinical criteria. Duration of treatment ranged from 2 to 8 days. Serum bilirubin levels at the end of phototherapy ranged from 6 to 10 mg/dl. No patient had laboratory evidence of hemolytic disease or hepatic dysfunction and none required an exchange transfusion. At the time of the study, all patients were being fed enterally with human breast milk and/or Special Care Formula (Ross Laboratories, Columbus, OH). Prior to enrollment in the study, informed consent was obtained from the patient's parents in accordance with the established guidelines of our Committee on Human Investigation.
Bilirubin analysis. Samples were obtained by heel stick or venipuncture under subdued light and immediately placed in foil-covered tubes; the serum was separated by centrifugation and stored at -20" C until analyzed. For each patient, one serum sample was obtained immediately following the discontinuation of phototherapy; two additional samples were drawn over the next 9 h. A final sample was obtained 12 to 24 h following cessation of phototherapy. The bilirubin isomer composition of these samples was determined by reversed-phase HPLC on a 0.46 x 25 cm Zorbax-ODs column (DuPont Instruments, Wilmington, DE) fitted with a precolumn with 0.1 M di-n-octylamine acetate in methanol, pH 7.7 as the eluant (5) logarithmic plots of the isomer concentration (from the integrated peak areas on the chromatograms) versus time.
The rate of thermal reversion of the configurational isomers to native bilirubin was determined by incubating serum samples (buffered to pH 7.4 by the addition of 0.05 M HEPES) at 37" C and monitoring the isomer composition by HPLC over 24 h.
Zrradiance measurements. The irradiance of the phototherapy units and of the ambient light in the nursery falling within the bilirubin absorption band (400 to 500 nm) was measured with an International Light IL700 radiometer and a SEE 400 broadband detector fitted with a filter (type TBLU, International Light, Newburyport, MA) which transmits light between 350 and 530 nm. The peak response of this detector-filter combination is at 468 nm with half-maximum sensitivity at 397 and 483 nm.
RESULTS
During phototherapy bilirubin is converted to more polar isomers which achieve steady-state levels in the serum within 3 to 4 h after the start of phototherapy (12, 14) . Figure 1 shows a typical HPLC analysis of serum from a patient who had been treated for 6 days with phototherapy. Chromatogram a is of serum obtained as phototherapy was stopped; chromatograms b and c are of samples obtained 3 and 6% h later, respectively. The major pigment, peak 1, is native 4Z,1 5Z-bilirubin. Peak 2 is the configurational photoisomer, 4Z-15E-bilirubin. A small amount of 4E,15Z-bilirubin is formed in vivo. However, it is not completely resolved from the 4Z,15E-isomer and in the chromatogram appears as a shoulder eluting slightly ahead of peak 2. Peak 3 is the structural isomer lumirubin (6), which has also been called photobilirubin I1 (15) and cyclobilirubin (16) .
Analyses of serum samples following the discontinuation of phototherapy in six premature infants revealed that the concentration of 4Z, 1 5E-bilirubin declined slowly. Figure 2 contains plots of configurational isomer concentration in the serum as a function of time after the end of phototherapy for these six infants. The rate of decline in photoisomer concentration appears to be first-order over the initial 8 to 10 h. After this initial period, the serum concentration of the photoisomer declined even more slowly. The serum half-life for the 4Z,15E-isomer calculated from the initial (more rapid) rate of disappearance ranged from 12 to 2 1 h, with a mean of 15 h. There was no correlation between the length of phototherapy treatment and rate of decline in configurational isomer concentration. In control experiments, there was negligible reisomerization of the configurational isomer back to native bilirubin in serum samples incubated for 24 h at 37" C in the dark. Therefore, the disappearance of the isomer from the serum was not simply the result of thermal reisomerization.
Lumirubin disappeared from the serum much more quickly than did the configurational isomer. Lumirubin is found in serum during and at the end of phototherapy (Fig. 1 a) , however, little or none was detectable in any ofthe serum samples obtained 2 to 3 h after stopping treatment (Fig. 1 b) . These results indicate that the half-life of lumirubin in the serum is less than 2 h, compared to the 12 to 2 1 h half-life of the configurational isomer.
DISCUSSION
Our results confirm previous reports that the principal photochemical reaction occumng in jaundiced infants treated with phototherapy is Z to E configurational isomerization of bilirubin (9-1 1). The rate of disappearance of bilirubin configurational isomers from the serum of preterm infants is very slow. Lamola et al. (13) reported a more rapid elimination of isomer in 3-yrold girl with Crigler Najjar (I) syndrome. The estimate of configurational isomer concentration provided by the fluorescent assay used by these investigators may have been inaccurate because of interference from lumirubin (8) . Alternatively, the difference between our data and that of Lamola et al. (13) may indicate that this older child had a faster excretory rate for the configurational isomer than premature infants.
Our interpretation of the slow decline in the serum concentration of 4Z,15E-bilirubin is that this isomer is excreted slowly by preterm infants. It is unlikely that the slow serum decline is either the result of ongoing isomer production after the end of phototherapy, or the result of migration of isomer from an extravascular pool into the circulation to replace excreted pigment. Ongoing production of photoisomer is unlikely to affect our calculated serum half-life for two reasons. First, all of the patients were studied in our level I1 nursery where the ambient light level is lower than that in the neonatal intensive care unit. Second, even in the intensive care unit, the highest amount of 4Z715E-isomer produced is 6% of the total ( 12). We have calculated the isomer half-life from the initial rate of disappearance which begins with 15 to 20% of the bilirubin as the configurational isomer. [Ongoing production may be the cause of the slower decline in photoisomer concentration observed after the initial 8 to 10 h (Fig. 2) .]
The migration of isomer from an extravascular pool into the plasma to replace excreted pigment could cause the measured decline in serum concentration to be slower than the rate of excretion. However, only if the rate of migration were slower than the rate of excretion would this migration affect the measurement. Recent studies suggest that equilibration of the 4Z,15E-isomer between sites of formation in the tissues and the plasma is rapid. In premature infants the percentage of the plasma bilirubin which is converted to the configurational isomer approaches the photochemically defined equilibrium value within 3 to 4 h of the start of phototherapy (12) . This observation indicates that the rate of exchange of 4Z,1 5E-isomer between the tissue pool and the vascular pool is rapid (i.e. a half-life -2 h) compared with the rate of disappearance of isomer from the serum (Fig. 2) . Thus the rate of disappearance of the 4Z, 15E-isomer from the serum is a measure of its rate of excretion.
If the secretion of the configurational isomer is as slow as suggested by our measured serum half-life, then the clinical response to phototherapy requires the excretion of other photoproducts. The serum half-life can be used to estimate a maximum rate at which bilirubin can be eliminated by excretion of this isomer. If the plasma concentration of bilirubin is 20 mg/dl and the hematocrit equal to 50%, the total body load of bilirubin would be 17 mg/kg body weight (1 7, 18), assuming the blood volume to be 85 ml/kg body weight. The maximum percentage of the total bilirubin present as the configurational isomer is 20%, therefore only 3.4 mg/kg of bilirubin are in the excretable pool (half of this pool is intravascular and half extravascular). The configurational isomer is eliminated with first-order kinetics with a half-life of 15 h (Fig. 2) , thus each hour 4.5% of the pool is excreted. Therefore, if the excretable pool is kept at 3.4 mg/kg and there is no enterohepatic recirculation of excreted pigment, as much as 3.7 mg/kg/24 h can be eliminated. Daily production of bilirubin in normal (nonhemolytic) newborn infants is approximately 8.5 mg/kg/24 h (19) . Tan has found a 35% reduction in serum bilirubin/24 h with moderate intensity phototherapy (20) . For an infant with an initial bilirubin concentration of 20 mg/dl this reduction would require excretion of 8.5 mg bilirubin per kg plus all of the daily production for a total of 17 mg/kg/ 24 h. In full-term, nonjaundiced infants elimination of native bilirubin is estimated to be less than 6 mg/kg/24 h (19) . Therefore a typical therapeutic response to phototherapy requires elimination of 11 mg/kg/24 h of which, at most, 4 mg/kg/day can be accounted for by excretion of the configurational isomer. It is clear that other mechanisms of bilirubin elimination must occur during phototherapy.
The second fastest photoehemical reaction of bilirubin is structural isomerization to lumirubin (6) . During phototherapy the serum concentration of lumirubin is lower than the concentration of the configurational isomers: 2 to 6 versus 15 to 20% of the total serum bilirubin. [Note that in Fig. 1 a the peak areas do not reflect the relative concentrations of the bilirubin isomers, because of different molar extinction coefficients at 465 nm (21) .] However, lumirubin is cleared from the serum more rapidly than is the configurational isomer. Because lumirubin has nearly disappeared from the serum by the time of our second blood sample, our data do not allow a precise calculation of its serum half-life, but it must be less than 2 h. Thus, although lumirubin is a minor photoproduct in terms of serum concentration, because of its efficient excretion lumirubin may play a quantitatively important role in the therapeutic response to phototherapy.
In summary, the principal in vivo photochemical reactions of bilirubin are configurational and structural isomerization. In the human infant undergoing phototherapy, the rate determining step in the elimination of unconjugated bilirubin appears not to be the formation of these polar isomers, but rather their elimination. In the premature infant, the elimination of the configurational isomers is too slow to account for the clinically observed decline in serum bilirubin. Lumirubin, which is a minor photoproduct, may be important in vivo because of its rapid excretion. Further studies are required to determine the contribution of lumirubin formation and excretion to the decline in serum bilirubin concentration produced by phototherapy.
